Share Name Share Symbol Market Type Share ISIN Share Description
Dechra Pharm LSE:DPH London Ordinary Share GB0009633180 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +15.00p +1.09% 1,393.00p 1,390.00p 1,393.00p 1,395.00p 1,359.00p 1,359.00p 322,989 16:35:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 247.6 14.5 14.0 99.5 1,291.97

Dechra Pharm (DPH) Latest News

More Dechra Pharm News
Dechra Pharm Takeover Rumours

Dechra Pharm (DPH) Share Charts

1 Year Dechra Pharm Chart

1 Year Dechra Pharm Chart

1 Month Dechra Pharm Chart

1 Month Dechra Pharm Chart

Intraday Dechra Pharm Chart

Intraday Dechra Pharm Chart

Dechra Pharm (DPH) Discussions and Chat

Dechra Pharm Forums and Chat

Date Time Title Posts
16/9/201611:35Dechra Pharmaceuticals Plc279
10/3/201216:11LOOKING TO BUY DECHRA PHARMACEUTICAL88
10/3/201216:10Dechra with Charts9
10/3/201216:10Dechra Pharmaceuticals PLC1

Add a New Thread

Dechra Pharm (DPH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
17:15:041,388.0015,000208,200.00O
16:47:251,375.2480111,015.70NT
16:35:111,393.003034,220.79NT
16:35:011,393.0026,810373,463.30UT
16:29:351,390.0011152.90AT
View all Dechra Pharm trades in real-time

Dechra Pharm (DPH) Top Chat Posts

DateSubject
30/9/2016
09:20
Dechra Pharm Daily Update: Dechra Pharm is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DPH. The last closing price for Dechra Pharm was 1,378p.
Dechra Pharm has a 4 week average price of 1,357.65p and a 12 week average price of 1,320.44p.
The 1 year high share price is 1,423p while the 1 year low share price is currently 811p.
There are currently 92,746,998 shares in issue and the average daily traded volume is 134,722 shares. The market capitalisation of Dechra Pharm is £1,291,965,682.14.
12/7/2016
14:46
steeplejack: Consensus eps for the year to end June 2017 is for eps of around 51p,putting the stock on a prospective PE of 24,yielding 1.7% .With 20% growth anticipated in the 2016/17 year,the PEG ratio is an undemanding 1.2 Difficult to see the stock pushing ahead aggressively from here but with a full year of the US acquisitions to be accounted for, any sterling weakness could benefit the share price.This is a relatively illiquid,thin share market .The shares have a history of retrenching after a share price run but if fresh institutional buyers emerge,which is quite possible in these nervous markets,the stock could yet surprise on the upside.
22/10/2010
21:34
gopher: This looks a fairly expensive purchase based on Sales/Profits. $42ml for a company turnover of $10m albeit with profits of $4ml; also up to a further $20ml if sales increase. Still what do I know as share price has risen but USA is a traditional acquisitions graveyard for british companies.
22/4/2007
21:19
mallet3: DPH is one of the hidden gems that few people know about. It is an essential part of any portfolio. Good solid growth, decent divi yield, excellent mgmt, expanding markets, new territories and much more. Treating companion animals is a niche the big boys have not been to bothered with, leaving DPH the chance to make hay. The fact that Dresdner have picked up coverage means more people will be attracted to the company, which will do no harm to the share price. Just because the mkt cap is not huge it does not make a company like this a huge risk to invest in. I am looking forward to holding on for another four years of good solid defensive (but not pedestrian) growth!!!
19/4/2006
18:50
shuisky: There has been a delay, and revenue streams forecasts from US approvals have had to be pushed further out. The share price was hit as a consequence. So short term your broker was right, but I hoped he advised you back in after the share had fallen! Frankly, I don't go for this kind of chopping & changing because you can very easily miss the move. The stock's undervalued, IMHO, and the recent fall made it even more undervalued. The selling creates an entry point opportunity, and those of us who are long term holders have preferred to top up at low levels. Does a delay in say 6 months for approval really make DPH undervalued at current levels? What's the worst that can happen here? The worst case scenario is that they don't get approval and you are left holding a cash-cow company generating 5-6% free cash flow, with low single digit growth prospects, but who still has the ability to increase margins by increasing pharma sales in Europe/UK. The downside is limited, and the upside is attractive.
05/9/2005
11:56
the old codger: That's tomorrow - I must say I am impressed with the slow but inexorable progress of the share price in front of the figures - hopefully the figs will satisfy everyone and further progress will be seen. Great also to see so few posters here! IMHO DYOR TOC
17/2/2005
12:14
lbo: BROKER RECOMMENDATIONS TODAY Evolution says buy Amstrad and add Dechra! Also The telegraph article on the 10th said! "Investors looking for a relatively uneventful but offbeat investment could do worse than plump for Dechra, the Yorkshire-based pharmaceuticals company. Dechra's share price has been on a steady trajectory upwards since January 2003 when it issued a profits warning. Its share price is trading at 198p, up 4½p yesterday, valuing the company at £100m. It has risen consistently thanks to generally positive results, an enduring market share and new products. Yesterday, it announced a further expansion in its range of veterinary products. One is Ovuplant – a controlled-release synthetic hormone used to stimulate ovulation in horses. Another, for dogs, is a drug called Vetoryl and the company has launched a new capsule size for smaller pooches. The company has secured UK authorization of the product and will begin marketing it later this year. Vetoryl's UK sales currently stand at £1m a year, and management claim that the US market is 10 times bigger – the drug has been granted a fast-track review by the US Food and Drug Administration. The company said in January that market conditions were improving. It expects to increase market share and deliver interim sales growth of 10pc. Analysts predict sales this year to climb to £198m, up from £187m last year. Adjusted profits are forecast to rise to £9.2m, up from £8.1m. This puts the shares on a forward rating of 16 times earnings, falling to 14.6 times in 2006. As with all pharma companies nothing is certain, but Dechra looks cheap. And it pays a dividend.
Dechra Pharm share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20160930 20:22:28